Shares of Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) have received a consensus rating of “Hold” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a hold rating. The average 12 month price target among brokerages that have issued a report on […]
Design Therapeutics (NASDAQ:DSGN – Free Report) had its price target decreased by Royal Bank of Canada from $7.00 to $4.00 in a report published on Tuesday morning, Benzinga reports. Royal Bank of Canada currently has a sector perform rating on the stock. A number of other research firms have also issued reports on DSGN. SVB […]
Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 3,120,000 shares, an increase of 6.1% from the October 15th total of 2,940,000 shares. Based on an average trading volume of 938,000 shares, the short-interest ratio […]
Design Therapeutics (NASDAQ:DSGN – Get Free Report) was downgraded by investment analysts at Piper Sandler from an “overweight” rating to a “neutral” rating in a note issued to investors on Tuesday, Briefing.com reports. They currently have a $6.00 target price on the stock, down from their previous target price of $42.00. Piper Sandler’s price target […]
Shares of Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) have earned a consensus rating of “Hold” from the six research firms that are covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating. The average twelve-month price objective among analysts that have covered the stock in the […]